Date: 2013-01-08
Type of information: Licensing agreement
Compound: microRNA therapeutics (LNA drugs against up to six additional microRNA targets)
Company: Santaris Pharma (Denmark) miRagen Therapeutics (USA)
Therapeutic area: Cardiovascular diseases
Type agreement: licensing
Action mechanism:
Disease: cardiovascular diseases
Details: Santaris Pharma and miRagen Therapeutics have expanded their existing partnership in the field of microRNA therapeutics. Under the expanded agreement, miRagen obtains a broad non-exclusive license in the miRNA therapeutics field for therapeutics research and worldwide exclusive rights to research, develop and commercialize LNA drugs against up to six additional microRNA targets that have been shown to be important in human disease areas of high unmet need. This brings the total number of microRNA targets under the agreement to ten.
On June 23, 2010, Santaris Pharma and miRagen Therapeutics, had formed a strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular diseases. miRagen had licensed rights to utilize Santaris Pharma A/S proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against miRagen’s proprietary microRNA targets for the treatment of cardiovascular disease
Santaris Pharma obtains a minority equity interest in miRagen in addition to milestone payments and royalties on LNA-based medicines developed as part of the collaboration.
Financial terms: Santaris Pharma A/S will receive a combination of cash and equity in consideration for the licenses as well as clinical milestones and royalties on products emerging from the alliance. Financial terms were not disclosed.
Latest news:
